Autolus Therapeutics Plc · NASDAQ:AUTL
Autolus Therapeutics — Q2 2025 Earnings Presentation
14 slides from Autolus Therapeutics's earnings presentation, Aug 12, 2025
Slide 1: Q2 2025 Financial Results and Business Updates
Q2 2025 Financial Results and Business Updates August 12, 2025 For Investor communication only. Not for use in product promotion. Not for further distribution. Autolus.com
Slide 2: Disclaimer
Developing and Delivering a New Generation of T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical fact
Slide 3: Agenda
Developing and Delivering a New Generation of T Cell Therapies Agenda • Welcome and Introduction: Amanda Cray, ED, Investor Relations & External Communications • Operational Highlights: Dr. Christian Itin, CEO • Financial Results: Rob Dolski, CFO • Upcoming Milestones and Conclusion: Dr. Christian I
Slide 4: Strong momentum in second quarter of the U.S. AUCATZYL launch
Developing and Delivering a New Generation of T Cell Therapies Strong momentum in second quarter of the U.S. AUCATZYL® launch AUCATZYL Net Product Sales 46 Treatment Centers Authorized as of 08/12/25 Q2 2025: $20.9 million Six Months Ended June 30, 2025: $29.9 million Physician interest based upon p
Slide 5: AUCATZYL geographic growth opportunities in ALL
Developing and Delivering a New Generation of T Cell Therapies AUCATZYL geographic growth opportunities in ALL Expansion Conditional marketing authorization in the UK received April 2025 • Meeting with NICE planned European Commission (EC) conditional approval received July 2025 Potential New •
Slide 6: 38.4% of responders remain in remission without subsequent treatment
Developing and Delivering a New Generation of T Cell Therapies 38.4% of responders remain in remission without subsequent treatment EHA extended data cut: Patient status at 3 years of follow up Infused Current data cut: 18 Jan 2025; N=127 No response or not evaluable median follow up: n=28 32.8 mont
Slide 7: Data continue to show long-term remissions in r/r adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Data continue to show long-term remissions in r/r adult B-ALL Probability of remaining in remission after 24 months was 54.1% censoring for consolidative SCT Jae H Park et al, EHA 2025, oral presentation #S113 7
Slide 8: Data continue to show long term remissions in r/r adult B-ALL
Developing and Delivering a New Generation of T Cell Therapies Data continue to show long term remissions in r/r adult B-ALL At 24 months, overall survival probability was 46.0% Jae H Park et al, EHA 2025, oral presentation #S113 8
Slide 9: Plans for obe-cel development in oncology and autoimmune diseases
Developing and Delivering a New Generation of T Cell Therapies Plans for obe-cel development in oncology and autoimmune diseases Obe-cel characteristics borne out across multiple studies INDICATION STUDY PHASE Development Plans Adult B-ALL FELIX Approved Pediatric B-ALL CATULUS Phase 1 Pediatric ALL
Slide 10: Financial Results
Financial Results
Slide 11: Financial summary – key metrics
Developing and Delivering a New Generation of T Cell Therapies Financial summary – key metrics* USD ($’ 000) Q2 2025 Q2 2024 Variance Product revenue, net 20,923 - 20,923 Cost and operating expenses: Cost of sales (24,445) - (24,445) Research and development expenses, net (27,430) (36,612) 9,182 Sel
Slide 12: Upcoming news flow
Upcoming news flow
Slide 13: Upcoming milestones
Developing and Delivering a New Generation of T Cell Therapies Upcoming milestones Anticipated Milestone or Catalyst Anticipated Timing Initial data from PY01 trial in pediatric ALL H2 2025 SLE Phase 1 trial presentation at American College of Rheumatology (ACR) Q4 2025 First patient dosed in Phase
Slide 14: Thank you
Thank you Autolus.com